More about NATCO Pharma Limited
Fundamentals for NATCO Pharma Limited
Regulatory Filings for NATCO Pharma Limited
From COVID Debt to Green Despair: Industrial Discharge Is Destroying India’s Last Prawn Nurseries
The Hidden Cost of India's Electronics Assembly Push: A 40% E-Waste Surge and the Death of Affordable Repair
The Wedding Loan Trap: How India’s Microfinance Boom Turned Housewives Into Ghost Borrowers and Temple Brass Into EMI Cash
From Lifesaving Drugs to Sick Units: The Hidden Energy Crisis Inside India’s Pharma Clusters
Technicals for NATCO Pharma Limited
Price Summary
NATCO Pharma Limited's stock opened at 1093.65 on 2026-04-30, surged to 1106.95, hit a low of 1087.0, and closed up 0.19% at 1095.75, with 387663 shares traded.The highest price the stock achieved in the past 52 weeks is 1123.7, while the lowest price it saw is 792.95.
Analysts expect the price of NATCOPHARM to vary between 712.0 and 1180.0, with an average expected price near 938.1.
Technicals
Support and Resistance: The current price of 1095.75 for NATCOPHARM finds support at 1016.15 and resistance at 1100.05. These levels define a range in which the price might oscillate, with 1016.15 as a potential support and 1100.05 as a resistance level.Aroon: The current reading of the AROON is neutral, offering no clear signals for a movement in either direction. This suggests that the market may be in a holding pattern, with no dominant trend in place.
Bol. Bands: The BOLL BANDS is in a neutral stance, not pointing to a clear trend in either direction. This suggests that the market may be lacking strong momentum, making it difficult to predict the next move.
Parabolic SAR: The PSAR for NATCOPHARM continues to signal a bearish stance, reinforcing a resistance level that could restrict upward movement. This resistance suggests that the market may remain under bearish pressure, with limited potential for breaking higher.
Stochastic: The current reading of the STOCHASTIC is neutral, offering no clear signals for a movement in either direction. This suggests that the market may be in a holding pattern, with no dominant trend in place.
Tripple Moving Agerage: The 20, 50, and 100 moving averages are aligned in a bearish pattern, signaling a downtrend. However, the slopes of the 20 and 50 SMAs are starting to waver, suggesting that the bearish momentum may be weakening. This could be an early sign of a potential bullish reversal for NATCOPHARM, as the market's downward trajectory begins to lose strength and a possible shift towards more positive price action may occur soon.
The technical analysis of a company's stock performance is valuable, but only when considered in conjunction with the company's fundamentals. These fundamentals, including financial strength, earnings growth, and leadership, provide a foundation for understanding market movements. Additionally, industry trends and competitive pressures play an important role. By integrating both fundamental and technical analysis, one can better evaluate the company's true potential and make more informed investment decisions.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
From Price Pressures to Profit Power: The MSME Playbook Redefining India’s Economy
₹90 Crore Bet Signals a Massive Shift in India’s Rural Economy
The Hidden Engine of Global Growth: Why India Is Becoming Impossible to Overlook